This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wong, J M Articles by Esdaile, J M Search for Related Content PubMed PubMed Citation Articles by Wong, J M Articles by Esdaile, J M Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Lupus Hazardous Substances DB METHOTREXATE Social Bookmarking                         What's this?

Methotrexate in systemic lupus erythematosus

Arthritis Research Centre of Canada and the University of British Columbia, Vancouver, Canada

J M Esdaile

Arthritis Research Centre of Canada and the University of British Columbia, Vancouver, Canada, JEsdaile{at}arthritisresearch.ca

The most appropriate treatment of moderate, nonorgan threatening disease activity in systemic lupus erythematosus (SLE) remains poorly defined, although methotrexate (MTX) is commonly used. The results of 20 uncontrolled case series and a single retrospective cohort study tend to support its use to treat active skin and joint disease. Unfortunately, three prospective randomized trials have reported conflicting results. Two reported improvement in overall disease activity and decreased corticosteroid requirement with MTX. The third trial showed no benefit from MTX for disease activity, but did report a reduction in corticosteroid requirements. Difficulties in conducting trials in moderately active SLE are discussed.

Key Words: clinical trial • discontinuation trial • Methotrexate • systemic lupus erythematosus

Lupus, Vol. 14, No. 2, 101-105 (2005)
DOI: 10.1191/0961203305lu2043rr


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K Visser, W Katchamart, E Loza, J A Martinez-Lopez, C Salliot, J Trudeau, C Bombardier, L Carmona, D van der Heijde, J W J Bijlsma, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative Ann Rheum Dis, July 1, 2009; 68(7): 1086 - 1093. [Abstract] [Full Text] [PDF]

				S. Sliesoraitis, R. Khan, and J. Rothman Methotrexate-Induced Hodgkin Disease in a Patient With Systemic Lupus Erythematosus J Am Osteopath Assoc, June 1, 2009; 109(6): 325 - 328. [Abstract] [Full Text] [PDF]

				C. A. Heyneman Systemic Lupus Erythematosus: A Therapeutic Update Journal of Pharmacy Practice, February 1, 2009; 22(1): 29 - 52. [Abstract] [PDF]

				I N Bruce The influence of other drugs on coronary heart disease (CHD) risk in systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 23 - 26. [Abstract] [PDF]

				J Wenzel Letter to the Editor Lupus, July 1, 2005; 14(7): 569 - 569. [PDF]